Publication

Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research

Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Maelandsmo, G. M., Roman-Roman, S., Seoane, J., Trusolino, L., Villanueva, A. & EurOPDX Consortium, Sep-2014, In : Cancer discovery. 4, 9, p. 998-1013 16 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Hidalgo, M., Amant, F., Biankin, A. V., Budinska, E., Byrne, A. T., Caldas, C., ... EurOPDX Consortium (2014). Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer discovery, 4(9), 998-1013. https://doi.org/10.1158/2159-8290.CD-14-0001

Author

Hidalgo, Manuel ; Amant, Frederic ; Biankin, Andrew V. ; Budinska, Eva ; Byrne, Annette T. ; Caldas, Carlos ; Clarke, Robert B. ; de Jong, Steven ; Jonkers, Jos ; Maelandsmo, Gunhild Mari ; Roman-Roman, Sergio ; Seoane, Joan ; Trusolino, Livio ; Villanueva, Alberto ; EurOPDX Consortium. / Patient-Derived Xenograft Models : An Emerging Platform for Translational Cancer Research. In: Cancer discovery. 2014 ; Vol. 4, No. 9. pp. 998-1013.

Harvard

Hidalgo, M, Amant, F, Biankin, AV, Budinska, E, Byrne, AT, Caldas, C, Clarke, RB, de Jong, S, Jonkers, J, Maelandsmo, GM, Roman-Roman, S, Seoane, J, Trusolino, L, Villanueva, A & EurOPDX Consortium 2014, 'Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research', Cancer discovery, vol. 4, no. 9, pp. 998-1013. https://doi.org/10.1158/2159-8290.CD-14-0001

Standard

Patient-Derived Xenograft Models : An Emerging Platform for Translational Cancer Research. / Hidalgo, Manuel; Amant, Frederic; Biankin, Andrew V.; Budinska, Eva; Byrne, Annette T.; Caldas, Carlos; Clarke, Robert B.; de Jong, Steven; Jonkers, Jos; Maelandsmo, Gunhild Mari; Roman-Roman, Sergio; Seoane, Joan; Trusolino, Livio; Villanueva, Alberto; EurOPDX Consortium.

In: Cancer discovery, Vol. 4, No. 9, 09.2014, p. 998-1013.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C et al. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer discovery. 2014 Sep;4(9):998-1013. https://doi.org/10.1158/2159-8290.CD-14-0001


BibTeX

@article{4793c800e2ab48cfb8a63d685f0371c7,
title = "Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research",
abstract = "Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. (C) 2014 AACR.",
keywords = "HUMAN PANCREATIC-CANCER, TUMOR XENOGRAFTS, NUDE-MICE, COLORECTAL-CANCER, STEM-CELLS, IN-VIVO, PERSONALIZED CHEMOTHERAPY, THERAPEUTIC RESPONSE, IMMUNODEFICIENT MICE, DRUG DEVELOPMENT",
author = "Manuel Hidalgo and Frederic Amant and Biankin, {Andrew V.} and Eva Budinska and Byrne, {Annette T.} and Carlos Caldas and Clarke, {Robert B.} and {de Jong}, Steven and Jos Jonkers and Maelandsmo, {Gunhild Mari} and Sergio Roman-Roman and Joan Seoane and Livio Trusolino and Alberto Villanueva and {EurOPDX Consortium}",
note = "{\circledC}2014 American Association for Cancer Research.",
year = "2014",
month = "9",
doi = "10.1158/2159-8290.CD-14-0001",
language = "English",
volume = "4",
pages = "998--1013",
journal = "Cancer discovery",
issn = "2159-8274",
publisher = "AMER ASSOC CANCER RESEARCH",
number = "9",

}

RIS

TY - JOUR

T1 - Patient-Derived Xenograft Models

T2 - An Emerging Platform for Translational Cancer Research

AU - Hidalgo, Manuel

AU - Amant, Frederic

AU - Biankin, Andrew V.

AU - Budinska, Eva

AU - Byrne, Annette T.

AU - Caldas, Carlos

AU - Clarke, Robert B.

AU - de Jong, Steven

AU - Jonkers, Jos

AU - Maelandsmo, Gunhild Mari

AU - Roman-Roman, Sergio

AU - Seoane, Joan

AU - Trusolino, Livio

AU - Villanueva, Alberto

AU - EurOPDX Consortium

N1 - ©2014 American Association for Cancer Research.

PY - 2014/9

Y1 - 2014/9

N2 - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. (C) 2014 AACR.

AB - Recently, there has been an increasing interest in the development and characterization of patient-derived tumor xenograft (PDX) models for cancer research. PDX models mostly retain the principal histologic and genetic characteristics of their donor tumor and remain stable across passages. These models have been shown to be predictive of clinical outcomes and are being used for preclinical drug evaluation, biomarker identification, biologic studies, and personalized medicine strategies. This article summarizes the current state of the art in this field, including methodologic issues, available collections, practical applications, challenges and shortcomings, and future directions, and introduces a European consortium of PDX models.Significance: PDX models are increasingly used in translational cancer research. These models are useful for drug screening, biomarker development, and the preclinical evaluation of personalized medicine strategies. This review provides a timely overview of the key characteristics of PDX models and a detailed discussion of future directions in the field. (C) 2014 AACR.

KW - HUMAN PANCREATIC-CANCER

KW - TUMOR XENOGRAFTS

KW - NUDE-MICE

KW - COLORECTAL-CANCER

KW - STEM-CELLS

KW - IN-VIVO

KW - PERSONALIZED CHEMOTHERAPY

KW - THERAPEUTIC RESPONSE

KW - IMMUNODEFICIENT MICE

KW - DRUG DEVELOPMENT

U2 - 10.1158/2159-8290.CD-14-0001

DO - 10.1158/2159-8290.CD-14-0001

M3 - Review article

VL - 4

SP - 998

EP - 1013

JO - Cancer discovery

JF - Cancer discovery

SN - 2159-8274

IS - 9

ER -

ID: 13975490